ArticleMedicine2017

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.

Bin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.